Exact Sciences Corporation (NASDAQ:EXAS) vs. Its Peers Head to Head Review

Exact Sciences Corporation (NASDAQ: EXAS) is one of 206 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Exact Sciences Corporation to related companies based on the strength of its dividends, earnings, profitability, risk, institutional ownership, analyst recommendations and valuation.

Volatility & Risk

Exact Sciences Corporation has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, Exact Sciences Corporation’s rivals have a beta of 1.55, indicating that their average stock price is 55% more volatile than the S&P 500.

Insider and Institutional Ownership

85.4% of Exact Sciences Corporation shares are held by institutional investors. Comparatively, 46.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 4.0% of Exact Sciences Corporation shares are held by insiders. Comparatively, 13.9% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Exact Sciences Corporation and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Exact Sciences Corporation -60.71% -30.32% -27.37%
Exact Sciences Corporation Competitors -3,950.05% -121.20% -44.20%

Earnings and Valuation

This table compares Exact Sciences Corporation and its rivals gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Exact Sciences Corporation $99.38 million -$167.21 million -52.04
Exact Sciences Corporation Competitors $220.75 million -$39.68 million -58.08

Exact Sciences Corporation’s rivals have higher revenue and earnings than Exact Sciences Corporation. Exact Sciences Corporation is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings for Exact Sciences Corporation and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exact Sciences Corporation 0 4 9 0 2.69
Exact Sciences Corporation Competitors 493 2381 6483 122 2.66

Exact Sciences Corporation presently has a consensus target price of $50.46, indicating a potential downside of 16.41%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.64%. Given Exact Sciences Corporation’s rivals higher possible upside, analysts plainly believe Exact Sciences Corporation has less favorable growth aspects than its rivals.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply